Business
PTC Therapeutics to Present Clinical and Real-World Evidence on Translarna™ at the Annual Congress of the World Muscle Society
- Presentations include age of loss of ambulation and preservation of upper limb function following treatment with Translarna in patients with nonsense
About this update from Ptc Therapeutics, Inc.
[{"type":"text","content":"- Presentations include age of loss of ambulation and preservation of upper limb function following treatment with Translarna in patients with nonsense mutation Duchenne muscular dystrophy -\nSOUTH PLAINFIELD, N.J., Oct. 11, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that recent clinical trial and real-world evidence on the efficacy and safety of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) will be presented at the 27th International Annual Congress of the World Muscle Society (WMS) in Halifax, Nova Scotia, Canada.\nKey presentations include:\nPosternumber \nTitle\nPoster session, location and time\nP19\nUpdated demographics and safety data from patients with nonsense mutation Duchenne muscular dystrophy receiving ataluren in the STRIDE Registry\nWednesday, Oct. 12, 2022 \nPoster session 1 \nMain poster area – Ballroom B1-B2\n14:30–16:00 – DMD - Clinical\nP22\nAge at loss of ambulation in patients with DMD from the STRIDE Registry and the CINRG Duchenne Natural History Study: a matched cohort analysis\nWednesday, Oct. 12, 2022\nPoster session 1 \nMain poster area – Ballroom B1-B2\n14:30–16:00 – DMD - Clinical\nP23\nPulmonary function in patients with Duchenne muscular dystrophy from the STRIDE Registry and CINRG Duchenne Natural History Study: a matched cohort analysis\nWednesday, Oct. 12, 2022\nPoster session 1 \nMain poster area – Ballroom B1-B2\n14:30–16:00 – DMD - Clinical\n LSVP37\nSafety and efficacy of ataluren in nmDMD patients from Study 041, a phase 3, randomized, double-blind, placebo-controlled trial\nFriday, Oct. 14, 2022 \nPoster session 4 \nMain poster area – Ballroom B1-B2\nePoster and virtual platform only\n LSVP26\nAtaluren preserves upper limb function in nmDMD patients from Study 041, a phase 3 placebo-controlled trial, and the STRIDE Registry\nFriday, Oct. 14, 2022 \nPoster session 4 \nMain poster area – Ballroom B1-B2\nePoster and virtual platform only\nThe full congress program can be found on the WMS website: https://www.wms2022.com/page/programme\nAbout Translarna™ (ataluren)\nTranslarna (ataluren), discovered and developed by PTC Therapeutics, is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an ...